The results of the largest study on the efficacy of the Pfizer vaccine against the coronavirus conducted to date was published Sunday night in Israel, providing some much-needed positive news. The research done by Clalit, the country’s largest health care provider and one of four state-mandated, subsidized health maintenance organizations in Israel, analyzed over one million individuals, half who received both doses of the shot. According to the results, those inoculated with two doses were 94% less likely to be infected and 92% less likely to be seriously ill, compared with people who did not get vaccinated at all. The study also found the Pfizer shot to be most effective – up to 99% – a week after receiving the second of the two required doses. Israel has become the world’s testing ground of sorts, vaccinating close to 4 million of its 9 million citizens with at least one dose. The world-leading pace and scope of the operation has afforded global health organizations the ability to inspect and reaffirm vaccination strategies and their effectiveness.